Wockhardt gets USFDA nod for generic eye drops

04 Jul 2011 Evaluate

Drug maker Wockhardt has received tentative approval from the US health regulator to market Olopatadine hydrochloride eye drops in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market 0.1% solution of Olopatadine hydrochloride eye drops, used in treating allergic conjunctivitis. Olopatadine hydrochloride eye drops are the generic equivalent of Alcon Laboratories Inc's Patanol brand.The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same. According to IMS Health data, the total market for Olopatadine in the US is nearly $230 million. Wockhardt is only one of the three companies to receive a tentative approval for this product till date. crackcrack

Wockhardt Share Price

1230.95 58.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.